Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01336296 · ClinicalTrials.gov registry record · Phase 4
Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients
A Phase 4 study of Kidney Transplant Recipients, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 4
- Development phase
- 61
- Enrollment target
- 1
- Study location
NCT01336296 is a Phase 4 study of Kidney Transplant Recipients that has completed, run by University of Cincinnati. The registered enrollment target is 61 participants, roughly in line with the 63-participant average among 4 other Kidney Transplant Recipients trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT01336296, a Phase 4 study of Kidney Transplant Recipients, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 61 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is specifically designed to determine whether the initiation of Myfortic 2 weeks prior to transplantation will enhance the therapeutic efficacy of Simulect induction therapy in low to moderate risk patients. Specifically, the addition of Myfortic pretransplant to Simulect induction will be compared to standard Myfortic therapy with Thymoglobulin induction starting at the time of transplant in kidney transplant recipients.
Conditions Studied
Interventions
- DRUG mycophenolic acid
Study Locations (1)
Ohio
- University of Cincinnati Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2010-09 |
| Est. Completion | 2014-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01336296
The ClinicalTrials.gov registry entry for NCT01336296 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 63-participant average among 4 other Kidney Transplant Recipients trials with a reported enrollment target. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Transplant Recipients appearing as the primary indexed condition, and to 1 intervention - of which mycophenolic acid is the first listed.
NCT01336296 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT01336296 about?
NCT01336296 is a clinical study titled "Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients". This study is specifically designed to determine whether the initiation of Myfortic 2 weeks prior to transplantation will enhance the therapeutic efficacy of Simulect induction therapy in low to moderate risk patients. Specifically, the addition of Myfortic pretransplant to Simulect induction will b...
What is the current status of trial NCT01336296?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 61 participants. The study started on 2010-09. Estimated completion is 2014-04.
What conditions does trial NCT01336296 study?
This clinical trial studies the following conditions: Kidney Transplant Recipients.
What interventions are being tested in trial NCT01336296?
The interventions under investigation include: mycophenolic acid (DRUG).
Who is sponsoring clinical trial NCT01336296?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01336296 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant Recipients
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients
RECRUITING · Phase 4
-
Pilot Trial of Supplemental Vitamin A and Nicotinamide
RECRUITING · Early Phase 1
-
COVID Protection After Transplant-Immunosuppression Reduction
COMPLETED · Phase 2
-
COVID-19 Protection After Transplant Pilot Study
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.